The actual demonstration of reversibility of several key manifestations of nGD, such as debilitating myoclonic epilepsy or inability to walk due to severe ataxia, has inspired us and others to use Ambroxol in patients with GBA1-PD, and even in non-GBA1-PD, hypothesizing that misfolding can occur to some degree also in individuals without mutations at the DNA level [10,11]. The gene discussed is GBA1; the disease is myoclonic epilepsy.